| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8537200 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2018 | 23 Pages |
Abstract
The increased levels of major brain monoamines in the model of AD supports the hypothesis of the important role of monoamines in the excessive synaptic excitation resulting in cognitive dysfunction in AD brain. The neuroprotective effect of PRP-1 as manifested by the recovery of monoaminergic system suggests this bioactive compound as a perspective therapeutic agent for the treatment of AD.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Konstantin Yenkoyan, Katarine Fereshetyan, Senik Matinyan, Vergine Chavushyan, Michail Aghajanov,